Business Context and Reporting Period
Company: Evogene Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: May 26, 2022
Reporting Period: First Quarter ended March 31, 2022
This filing serves as a cover document incorporating by reference a press release (Exhibit 99.1) announcing the company's financial results for the first quarter of 2022.
Key Financial Metrics
The provided text is a cover filing and does not contain specific numerical data. The actual financial results are located in the incorporated press release (Exhibit 99.1), which is not included in the input text. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
The filing text does not provide specific data to compare against prior periods. Material changes, if any, are detailed in the incorporated press release (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. The document explicitly notes that the statements of the President and CEO contained in the press release are excluded from incorporation into certain registration statements, but the text of those statements is not present in this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q1 2022 revenue, net loss, and cash position figures.
- Verify the specific details of the "statements of Evogene's President and CEO" which were excluded from incorporation into Form F-3 and Form S-8 registration statements.
- Confirm the company's liquidity status and runway based on the cash flow data in the full press release.
- Check for any updates on the company's core business operations or product pipeline mentioned in the full press release.